Evidence map›Paper›PMID 39199694›Full record

ArticleCancers2024

The Proapoptotic Action of Pyrrolidinedione-Thiazolidinone Hybrids towards Human Breast Carcinoma Cells Does Not Depend on Their Genotype.

Nataliya Finiuk, Yuliia Kozak, Agnieszka Gornowicz, Robert Czarnomysy, Marlena Tynecka, Serhii Holota, Marcin Moniuszko, Rostyslav Stoika, Roman Lesyk, Krzysztof Bielawski and 1 more

Abstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nataliya FiniukDepartment of Regulation of Cell Proliferation and Apoptosis, Institute of Cell Biology of National Academy of Sciences of Ukraine, Drahomanov 14/16, 79005 Lviv, Ukraine.ORCID 0000-0002-4112-8815
Yuliia KozakDepartment of Regulation of Cell Proliferation and Apoptosis, Institute of Cell Biology of National Academy of Sciences of Ukraine, Drahomanov 14/16, 79005 Lviv, Ukraine.ORCID 0000-0002-6793-0662
Agnieszka GornowiczDepartment of Biotechnology, Faculty of Pharmacy, Medical University of Bialystok, Kilinskiego 1, 15-089 Białystok, Poland.ORCID 0000-0002-0945-7870
Robert CzarnomysyDepartment of Synthesis and Technology of Drugs, Faculty of Pharmacy, Medical University of Bialystok, Kilinskiego 1, 15-089 Białystok, Poland.ORCID 0000-0002-7148-6111
Marlena TyneckaCentre of Regenerative Medicine, Medical University of Bialystok, Kilinskiego 1, 15-089 Białystok, Poland.ORCID 0000-0002-1693-7549
Serhii HolotaDepartment of Pharmaceutical, Organic and Bioorganic Chemistry, Danylo Halytsky Lviv National Medical University, Pekarska 69, 79010 Lviv, Ukraine.ORCID 0000-0002-9892-437X
Marcin MoniuszkoCentre of Regenerative Medicine, Medical University of Bialystok, Kilinskiego 1, 15-089 Białystok, Poland.
Rostyslav StoikaDepartment of Regulation of Cell Proliferation and Apoptosis, Institute of Cell Biology of National Academy of Sciences of Ukraine, Drahomanov 14/16, 79005 Lviv, Ukraine.ORCID 0000-0001-5719-2187
Roman LesykDepartment of Pharmaceutical, Organic and Bioorganic Chemistry, Danylo Halytsky Lviv National Medical University, Pekarska 69, 79010 Lviv, Ukraine.ORCID 0000-0002-3322-0080
Krzysztof BielawskiDepartment of Synthesis and Technology of Drugs, Faculty of Pharmacy, Medical University of Bialystok, Kilinskiego 1, 15-089 Białystok, Poland.ORCID 0000-0003-3187-4205
Anna BielawskaDepartment of Biotechnology, Faculty of Pharmacy, Medical University of Bialystok, Kilinskiego 1, 15-089 Białystok, Poland.

Funding

National Research Foundation of Ukraine 2020.02/0035Polish National Agency for Academic Exchange under the Strategic Partnerships program BPI/PST/2021/1/00002/U/00001Simons Foundation 1030281
6 · The paper itself

Abstract

The development of new, effective agents for the treatment of breast cancer remains a high-priority task in oncology. A strategy of treatment for this pathology depends significantly on the genotype and phenotype of human breast cancer cells. We aimed to investigate the antitumor activity of new pyrrolidinedione-thiazolidinone hybrid molecules

Indexed as

apoptosisautophagybreast carcinoma cellsERHER2 genotypeshybrid moleculesPRpyrrolidinedione–thiazolidinonetoxicity

Identifiers

PMID39199694
PMCPMC11352273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.